All In Biotech

Drug Trial Radar · NCT01628913

Efficacy and Safety of BEZ235 Compared to Everolimus in Patients With Advanced Pancreatic Neuroendocrine Tumors

Randomized Phase II Study of BEZ235 or Everolimus in Advanced Pancreatic Neuroendocrine Tumors

Last checked: Nov 19, 2026Latest source record: Apr 7, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

62

Actual

Start

Oct 2012

Primary completion

Sep 2014

Study completion Sep 2014

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Jun 27, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This was a multicenter, open label, randomized phase II study to evaluate the efficacy and safety of BEZ235 as compared to everolimus in patients with advanced, low to intermediate grade pancreatic neuroendocrine tumor (pNET).

Conditions

  • Pancreatic Neuroendocrine Tumors (pNET)

Interventions

  • BEZ235Drug

    BEZ235 400 mg bid p.o. (by mouth, twice daily)

  • EverolimusDrug

    Everolimus 10 mg qd p.o. (by mouth, daily)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Progression Free Survival (PFS)Time frame: up to approx. 18 months

Locations

26 sites in 8 countries. Site status is shown where the registry gives one.

  • Cedars Sinai Medical Center SC-3

    Los Angeles, California

  • University of Colorado Univ Colorado

    Aurora, Colorado

  • University of Kentucky Univ Kebtucky

    Lexington, Kentucky

  • Montefiore Medical Center SC

    The Bronx, New York

  • Novartis Investigative Site

    Lyon, France

  • Novartis Investigative Site

    Montpellier, France

  • Novartis Investigative Site

    Paris, France

  • Novartis Investigative Site

    Reims, France

  • Novartis Investigative Site

    Toulouse, France

  • Novartis Investigative Site

    Bologna, BO, Italy

  • Novartis Investigative Site

    Pisa, PI, Italy

  • Novartis Investigative Site

    Roma, RM, Italy

  • Novartis Investigative Site

    Amsterdam, Netherlands

  • Novartis Investigative Site

    Groningen, Netherlands

  • Novartis Investigative Site

    Kazan', Russia

  • Novartis Investigative Site

    Seville, Andalusia, Spain

  • Novartis Investigative Site

    Barcelona, Catalonia, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Catalonia, Spain

  • Novartis Investigative Site

    Madrid, Madrid, Spain

  • Novartis Investigative Site

    Madrid, Madrid, Spain

  • Novartis Investigative Site

    Lucerne, Switzerland

  • Novartis Investigative Site

    Glasgow, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    London, United Kingdom

  • Novartis Investigative Site

    Manchester, United Kingdom

  • Novartis Investigative Site

    Sheffield, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.